Unknown

Troscriptions is a physician-formulated supplement brand that produces pharmaceutical-grade buccal troches designed for fast absorption and targeted brain and cellular effects. The company emphasizes clinical credibility, precision dosing, and US manufacturing, and it markets troches for energy, focus, stress, sleep, and immune support. Leadership includes founder and Chief Science Officer Dr. Theodore Achacoso and CEO Boomer Anderson; the site also lists multiple clinicians and science writers. Troscriptions operates as Troscriptions LLC (Dover, DE), runs an active content program (podcast and blog), and highlights strong customer reviews and practitioner endorsements as core trust signals.

1. Physician-formulated, pharmaceutical-grade buccal troches as core product differentiator
2. Legal entity: Troscriptions LLC, headquartered in Dover, DE; visible leadership and clinical endorsements
3. Product line focused on targeted functional outcomes: energy, focus, stress, sleep, and immune support
4. Strong content/brand play: podcast, blog, practitioner channels, and subscription options

Troscriptions positions itself at the intersection of clinical credibility and consumer performance supplements, emphasizing physician formulation, precision dosing, and buccal delivery as premium differentiators. The brand targets health-optimization and practitioner channels alongside D2C consumers.

• Just Blue: troches positioned for sustained cellular energy and focus.
• Tro Calm: troches formulated to decrease anxiousness and promote calm focus.
• Blue Cannatine: troches targeting memory, recall, and clean focus.
• Tro Zzz: troches designed to help users fall asleep faster and improve sleep quality.
• Tro Mune: troches focused on immune support and inflammation reduction.

Prioritize quality, traceability, and clinical validation when engaging—Troscriptions buyers value physician involvement, precise dosing, and US manufacturing. Lead with manufacturing credentials (GMP, batch testing), small-batch flexibility for formula tweaks, and rapid prototyping for troche formats to address their product and practitioner-focused distribution channels.

A contract packager could offer precision dosing machinery for molded or scored lozenge/troche production, small-to-medium batch scale runs, and pharma-grade quality systems (GMP, COA generation, stability testing). Value-adds include USP/FDA-aligned QC protocols, certificate-of-analysis and retained-sample programs, secondary packaging and kitting for subscription fulfillment, and ingredient sourcing for high-purity actives. Challenges include regulatory labeling and claims for a functional lozenge format, moisture control and stability for buccal delivery, and ensuring consistent organoleptic/taste masking at scale. A contract packager experienced with nutraceuticals and specialty oral-dissolve formats would reduce time-to-market and support iterative clinician-driven reformulation.

U.S. dietary supplements market estimated at about USD 68.7 billion in 2025 (source: industry reports).

Reported CAGR ranges from about 6-8% (mid-single to high-single digits) depending on scope and report.

• Growing consumer demand for preventive health and personalized supplements
• Rise of alternative delivery formats and higher-bioavailability formulations (functional lozenges, chews, beverages)
• Ecommerce and subscription models increasing recurring revenue for D2C supplement brands

Founder and Chief Science Officer: Dr. Theodore (Ted) Achacoso. CEO: Boomer Anderson. Additional leadership includes Dr. Scott Sherr (COO) and named marketing and operations team members listed on the site.

Not available

Site and news pages highlight company activities including practitioner product launches and partnership announcements in 2025 and 2026, and the homepage notes an Inc. 5000 recognition. The brand runs events and a HOMeHOPe symposium series tied to its clinical community.

Prospect details are not publicly visible.